ReportWire

Tag: The Society of Thoracic Surgeons

  • New Research Highlights Superior Long-Term Survival with Multi-Arterial Coronary Artery Bypass Grafting Over Single Arterial Grafting

    New Research Highlights Superior Long-Term Survival with Multi-Arterial Coronary Artery Bypass Grafting Over Single Arterial Grafting

    [ad_1]

    Newswise — SAN ANTONIO (January 27, 2024) ─ A new study presented at The Society of Thoracic Surgeons’ 2024 Annual Meeting in San Antonio, Texas, examines the ongoing controversy surrounding the choice between multi-arterial grafting (MAG) and single arterial grafting (SAG) in coronary artery bypass grafting (CABG) for multivessel coronary revascularization.

    The research, spanning from 2008 to 2019 and involving over one million patients undergoing isolated CABG with more than two bypass grafts, found that multi-arterial grafting CABG is associated with superior long-term survival compared to single arterial grafting, establishing it as the preferred surgical strategy for multivessel revascularization. 

    “Multiple small studies have demonstrated a survival benefit of multi-arterial grafting. We wanted to know if this survival benefit of multi-arterial grafting observed in single-center studies would translate to a large national cohort,” said the study’s lead author, Joseph Sabik III, MD, University Hospitals.  “Using the STS Adult Cardiac Surgery Database, we were able to demonstrate that it does.”

     At 10 years, MAG demonstrated improved unadjusted (HR 0.59, 95% CI 0.58-0.61) and adjusted (HR 0.86, 95% CI 0.85-0.88) survival rates compared to SAG. A center volume of 10 or more MAG cases per year was associated with survival benefits. 

    MAG’s survival advantage over SAG was found in various subgroups, including stable coronary disease, acute coronary syndrome, and acute infarction. Notably, MAG showed superior survival for patients with a BMI less than 40, whereas patients with a BMI of 40 or higher had superior survival with SAG. Survival outcomes were equivalent between MAG and SAG for patients aged 80 years or older, and those with severe heart failure, renal failure, peripheral vascular disease, or obesity.

    Patient data was collected from the STS Adult Cardiac Surgery Database and linked to the National Death Index for comprehensive longitudinal survival analysis. Risk-adjustment measures, including inverse probability weighting and multivariable modeling, were implemented to ensure accurate comparisons.

    These findings have significant implications for clinicians and cardiac surgeons when deciding on the most appropriate multivessel revascularization approach.

    “The survival benefit of multi-arterial grafting was observed in nearly all patients, except in those 80 or older and in those with co-morbidities graded as severe, where multi and single-arterial grafting resulted in similar survival. The only patients where single arterial grafting resulted in better survival were severely obese,” said Dr. Sabik. 

     

    This research not only contributes valuable insights to the ongoing debate but also provides evidence-based guidance for healthcare professionals in optimizing patient outcomes during CABG procedures.

    ###

    Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 7,700 cardiothoracic surgeons, researchers, and allied healthcare professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.



    [ad_2]

    The Society of Thoracic Surgeons

    Source link

  • STS Announces Late-Breaker Research to Be Presented at the 2024 Annual Meeting

    STS Announces Late-Breaker Research to Be Presented at the 2024 Annual Meeting

    [ad_1]

    Newswise — SAN ANTONIO (January 27, 2024) — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 – 29 in San Antonio. The conference, healthcare’s leading scientific and educational convening specializing in cardiothoracic surgery, has a rich history of showcasing clinical trials with a strong foundation of detailed methodology and trusted data collection governed by ethical clinical principles.

    The event’s late-breaking trial sessions focus on studies anticipated to significantly influence advances in cardiothoracic patient care. In this fast-paced healthcare landscape, surgeons look for the latest evidence to identify new therapies or preventive measures and help inform the most effective treatment decisions.  

    Key late-breaking studies selected for presentation include:

    Longitudinal Follow-up of Elderly Patients After Esophageal Cancer Resection in the Society of Thoracic Surgeons General Thoracic Surgery Database

    The study defines characteristics associated with long-term survival following esophagectomy for cancer in the Medicare population, using the STS General Thoracic Surgery Database linked to Centers for Medicare and Medicaid Services data. The analysis included 4,798 patients from 207 STS sites who underwent esophagectomy between 2012-2019. The researchers found that Medicare patients undergoing esophagectomy for cancer exhibit identifiable predictors for long-term survival and readmission. The absence of pathologic T and N downstaging increases the risk for long-term mortality and readmission.

    These findings suggest opportunities to enhance clinical practice and improve outcomes for Medicare patients undergoing esophagectomy for cancer.

    Cardiac Surgery after Transcatheter Aortic Valve Replacement: Trends and Outcomes

    The researchers set out to document trends and outcomes in cardiac surgery following transcatheter aortic valve replacement (TAVR), a topic gaining importance as reports of subsequent cardiac operations and early TAVR explantations increase. Using the Society of Thoracic Surgeons Adult Cardiac Surgery Database, the study covers adult patients who underwent cardiac surgery after an initial TAVR from January 2012 to March 2023.

    The findings underscore the escalating need for both aortic and non-aortic valve cardiac surgeries following TAVR. They note a substantial increase in the frequency of these surgeries, emphasizing the importance of understanding outcomes. The observed elevated risk in these cases, as indicated by mortality and stroke rates, calls for careful consideration, particularly given the expanding use of TAVR across a broader range of age and risk profiles. The study suggests the need for ongoing assessment and longitudinal evidence to inform decision-making in the evolving landscape of TAVR applications.

    The STS 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation: Key Takeaways and How Do They Differ from the ACC/AHA Atrial Fibrillation Clinical Practice Guidelines?

    The Society of Thoracic Surgeons’ 2023 clinical practice guidelines for the surgical management of atrial fibrillation (AF) incorporates the latest evidence for surgical ablation (SA) and left atrial appendage occlusion (LAAO) across various clinical scenarios. It emphasizes the evolving role of surgical ablation and left atrial appendage occlusion in managing atrial fibrillation.

    Compared to the 2017 clinical practice guidelines, this latest version emphasizes SA in first-time, non-emergent cardiac surgery and its long-term benefits, an extension of the recommendation to perform SA in all patients with AF undergoing first-time, non-emergent cardiac surgery. Further guidance is provided for patients with structural heart disease and AF who are considered for transcatheter valve repair or replacement.

    The recommendations highlight the importance of a multidisciplinary team, comprehensive assessment, and long-term follow-up, with specific attention to diverse clinical scenarios. The Class I recommendation for LAAO and expanded use of SA signify the growing confidence in these interventions based on recent evidence.

    Impact of Surgical Factors on Event-Free Survival in the Randomized, Placebo-Controlled, Phase 3 Trial of Perioperative Pembrolizumab For Early-Stage Non-Small-Cell Lung Cancer

    New findings from the KEYNOTE-671 research study, focused on resectable early-stage non-small-cell lung cancer (NSCLC), have unveiled a significant breakthrough in the treatment landscape.

    The study, titled “Impact of Surgical-Related Data on Event-Free Survival in KEYNOTE-671,” demonstrated that neoadjuvant therapy with pembrolizumab plus chemotherapy did not delay surgery. Neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab provided meaningful improvement in EFS compared with neoadjuvant chemotherapy alone for resectable early-stage NSCLC regardless of clinical nodal status, baseline disease stage, or type of surgery.

    Note to editors: Abstracts are available upon request.

    # # #

    Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 7,700 cardiothoracic surgeons, researchers, and allied healthcare professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.

    [ad_2]

    The Society of Thoracic Surgeons

    Source link

  • The Society of Thoracic Surgeons 59th Annual Meeting – January 20-23, San Diego

    The Society of Thoracic Surgeons 59th Annual Meeting – January 20-23, San Diego

    [ad_1]

    Newswise — Credentialed press representatives are invited to attend The Society of Thoracic Surgeons’ 59th Annual Meeting and Exhibition, which will include late-breaking scientific research, thought-provoking lectures, cutting-edge technologies, and innovative cardiothoracic surgery products. This meeting is the preeminent educational event in cardiothoracic surgery.

    When: Saturday, January 21, to Monday, January 23, 2023

    Where: San Diego Convention Center – Press office is Room 27A

    STS 2023 Highlights:

    • Scientific sessions that cover hot, top-of-mind subjects such as controversies in transplant practices, the future of coronary revasularization, and CABG vs. multivessel percutaneous intervention.
    • Keynote lectures from high-profile speakers:
      • Francisco G. Cigarroa, MD, a renowned transplant surgeon and the first Hispanic to be named Chancellor of The University of Texas System, will share his experiences as a third-generation physician. (Vivien T. Thomas Lecture, Saturday, January 21, 8-9 a.m. PT. Livestream available.)
      • Peter K. Smith, MD, from the Duke University School of Medicine, will describe the evolution of the evidence base available for treatment selection for coronary artery disease. (C. Walton Lillehei Lecture, Monday, January 23, 9-9:45 a.m. PT. Livestream available.)
      • Vivien Thomas Symposium will focus on putting diversity, equity, and inclusion into action and mitigating health disparities. (Monday, January 23, 2:45-3:45 p.m. PT.)
    • A recorded press briefing that spotlights some of the most exciting research from the meeting.

    More details are available in the Annual Meeting program: https://www.eventscribe.net/2023/STS/

    Registered reporters will have access to:

    • Complimentary meeting registration
    • Renowned experts within the cardiothoracic surgery specialty
    • Embargoed press materials, abstracts, and presentation slides, and recorded press briefing

    The press office (Room 27A) can be made available for media use upon request during meeting hours, Saturday, January 21 through Monday, January 23. If no STS staff member is present in the press office,

    Press releases and abstracts will be available in advance of the meeting. Please contact STS Media Relations staff directly to schedule interviews and locate experts before and during the meeting, as well as to learn more information on the guest lecturers.

    ###

    Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing approximately 7,700 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.

    [ad_2]

    The Society of Thoracic Surgeons

    Source link